Surmodics Inc (SRDX) Files 10-K for the Fiscal Year Ended on September 30, 2017

GuruFocus.com
0

- By insider

Surmodics Inc (SRDX) files its latest 10-K with SEC for the fiscal year ended on September 30, 2017. Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. Surmodics Inc has a market cap of $435.250 million; its shares were traded at around $33.20 with a P/E ratio of 114.46 and P/S ratio of 6.26. Surmodics Inc had annual average EBITDA growth of 10.20% over the past five years.


For the last quarter Surmodics Inc reported a revenue of $20.1 million, compared with the revenue of $18.15 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $73.1 million, an increase of 2.4% from last year. For the last five years Surmodics Inc had an average revenue growth rate of 7.4% a year.

The reported diluted earnings per share was 29 cents for the year, a decline of 61.8% from the previous year. Over the last five years Surmodics Inc had an average EPS decline of 11.9% a year. The Surmodics Inc had an operating margin of 9.72%, compared with the operating margin of 23.62% a year before. The 10-year historical median operating margin of Surmodics Inc is 30.13%. The profitability rank of the company is 7 (out of 10).

At the end of the fiscal year, Surmodics Inc has the cash and cash equivalents of $16.5 million, compared with $25.0 million in the previous year. The company had no long term debt. Surmodics Inc has a financial strength rank of 9 (out of 10).

At the current stock price of $33.20, Surmodics Inc is traded at 21.4% premium to its historical median P/S valuation band of $27.35. The P/S ratio of the stock is 6.26, while the historical median P/S ratio is 5.14. The stock gained 38.20% during the past 12 months.

For the complete 20-year historical financial data of SRDX, click here.

This article first appeared on GuruFocus.


Advertisement

Recommended Stories